Anti-Cancer Drug Prevents, Reverses Cardiovascular Damage in Mouse Model of Premature Aging Disorder

Tuesday, October 7, 2008

An experimental anti-cancer drug can prevent — and even reverse — potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

In a study published in the Proceedings of the National Academy of Sciences, a team led by Francis S. Collins, M.D., Ph.D., of the National Human Genome Research Institute (NHGRI), and Elizabeth G. Nabel, M.D., director of the National Heart, Lung and Blood Institute (NHLBI), describes its effort to use transgenic mice to identify and test potential therapies for children with Hutchinson-Gilford progeria syndrome.

There currently are no treatments for progeria, which is estimated to affect about one child in 4 million. At birth, children with progeria appear normal. But soon growth slows, and the children begin to show signs of accelerated aging, such as hair loss, wrinkled skin and loss of body fat. The most lethal damage, however, occurs within the children’s major blood vessels. The children develop premature cardiovascular disease, which typically leads to death from heart attack or stroke at about the age of 13.

Building upon its past experiments in cells and mice, the NIH-led team examined the effects of the experimental cancer drug tipifarnib in a strain of mice genetically engineered to develop cardiovascular damage similar to that seen in progeria patients. Tipifarnib belongs to a class of drugs known as farnesyltransferase inhibitors (FTIs), which are being tested in people with myeloid leukemia, neurofibromatosis and other conditions. The team had previously found that FTI drugs could reverse structural abnormalities in skin cells taken from progeria patients and grown in the laboratory.

"This approach worked much better than we thought it would. Not only did this drug prevent these mice from developing cardiovascular disease, it reversed damage in mice that already had disease," said the study’s senior author, Dr. Collins, who is the former director of NHGRI and who continues to conduct research as a special volunteer in the Genome Technology Branch of NHGRI’s Division of Intramural Research.

Researchers emphasized that more work needs to be done to determine whether FTI drugs will reverse progeria-associated cardiovascular disease in humans the same way they do in mice. In children suffering from progeria, the cardiovascular disease process often remains relatively stable until late in life, when it dramatically accelerates.

"If these drugs are found to have similar effects in children, this could mark a major breakthrough for treating this devastating disease," said NHLBI’s Dr. Nabel, who was a co-author of the study. "In addition, these findings shed light on the potential role of FTI drugs to treat other forms of coronary artery disease."

In 2007, researchers led by Mark Kieran, M.D., Ph.D., at the Dana-Farber Cancer Institute in Boston launched a clinical trial of the FTI drug lonafarnib in 28 progeria patients, ranging in age from 3 to 15, from 16 countries. Results of that study are not expected for at least a year.

Earlier this year, in experiments involving a different type of mouse model for progeria, a group of French and Spanish researchers reported that a combination of statin and bisphosphonate drugs slowed development of the visible symptoms of aging and extended life spans in the animals. Both drugs act upon the same biological pathway as FTI drugs.

While progeria affects only a few dozen children worldwide, efforts aimed at untangling the biological roots of this rare disease may prove valuable in understanding the human aging process in general. "What we learn through studies of rare genetic disorders often has implications for more common conditions," said NHGRI Scientific Director Eric D. Green, M.D., Ph.D. "For example, a growing body of evidence indicates that all people produce small amounts of the mutant protein found in progeria patients, and that this protein may play roles in aging or longevity."

In addition to NHGRI and NHLBI, the team that conducted the most recent study included researchers from Emory University School of Medicine, Atlanta and CVPath Institute, Inc., Gaithersburg, Md.

Image Caption 1: Photomicrographs showing the blood vessel of an untreated mouse with progeria (left) compared to the blood vessel of a similar mouse treated with the farnsyltransferase inhibitor drug tipifarnib. The drug blocked loss of smooth muscle cells (stained green) in blood vessels, preventing the cardiovascular disease characteristic of progeria.

Image Caption 2: Untreated cells from children with the genetic disease progeria (left) compared to similar cells treated with farnesyltransferase inhibitors (FTIs). In the test tube, FTIs reverse the nuclear damage caused by the disease.

Image Caption 3: Megan, 5- a patient with Progeria.

Image Credit 1: Michelle Olive, NHGRI

Image Credit 2: Brian C. Capell, NHGRI

Image Credit 3: The Markesan Regional Reporter and The Progeria Research Foundation

Source: NIH

Permalink: http://www.sflorg.com/comm_center/medical/p601_40.html

Time Stamp: 10/7/2008 at 4:12:51 PM UTC